Clinical Trial

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC). This study aims to identify potential biomarkers that may predict treatment response by analyzing genetic data from blood and tissue samples. The study will focus on real-world clinical outcomes and the exploratory discovery of biomarkers associated with the efficacy of this treatment regimen.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-17.
Trial Details
NCT Number NCT06648057
Lead Sponsor CHA University
Conditions Biliary Tract Cancer, Cholangiocarcinoma
Enrollment 100 participants
Start Date 2024-09-23
Primary Completion 2026-09-23 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-18